CLINICAL TRIALS PROFILE FOR TIGECYCLINE
✉ Email this page to a colleague
All Clinical Trials for Tigecycline
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00079885 ↗ | Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2003-11-01 | To compare the efficacy and safety of tigecycline with those of levofloxacin in the treatment of subjects with CAP requiring hospitalization. The co-primary efficacy endpoints in the study will be the clinical response in the clinically evaluable population and the clinical response in the clinical modified intent-to-treat population at the TOC visit. The primary efficacy analyses will first determine whether tigecycline is noninferior to levofloxacin. If tigecycline is found to be noninferior, the analyses will determine whether tigecycline is statistically better than levofloxacin. |
| NCT00079976 ↗ | Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA) | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2003-10-01 | To evaluate the safety and efficacy of tigecycline in the treatment of selected serious infections caused by VRE. The primary efficacy endpoint will be the clinical response for all subjects. |
| NCT00079989 ↗ | Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2003-12-01 | To evaluate the safety and efficacy of tigecycline in the treatment of subjects with selected serious infections caused by resistant gram-negative bacteria, eg, Acinetobacter baumannii, Enterobacter species, Klebsiella pneumoniae or other resistant gram-negative pathogens, for whom antibiotics have failed or who cannot tolerate other appropriate antimicrobial therapies. The primary efficacy endpoint will be the clinical response. |
| NCT00080496 ↗ | Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2003-07-01 | To compare the efficacy and safety of the tigecycline regimen with that of the imipenem/cilastatin regimen in subjects with nosocomial pneumonia. |
| NCT00081575 ↗ | Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2004-01-01 | To compare the efficacy and safety of IV tigecycline to IV levofloxacin in the treatment of subjects with CAP requiring hospitalization. |
| NCT00081744 ↗ | Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2002-11-01 | Purpose: To provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Tigecycline
Condition Name
Clinical Trial Locations for Tigecycline
Trials by Country
Clinical Trial Progress for Tigecycline
Clinical Trial Phase
Clinical Trial Sponsors for Tigecycline
Sponsor Name
